FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200325111> ?p ?o ?g. }

• W4200325111 endingPage "38" @default.
• W4200325111 startingPage "38" @default.
• W4200325111 abstract "Introduction The National Institute of Health and Care Excellence (NICE) issued a supplementary advice in 2009 stating that treatments for patients with short life expectancies (<24 months) can exceed the cost-effectiveness threshold of GBP30,000 (EUR34,668) per additional quality-adjusted life-year (QALY), as long as the treatment is indicated for small patient populations and there is sufficient evidence that it extends life (≥ three months), compared with current National Health Service (NHS) treatments. This study investigated how often NICE reimburses treatments that meet end-of-life (EOL) criteria. Methods Health technology assessments (HTAs) conducted by NICE from 2009 to 2020 were reviewed for approved oncology drugs. Terminated appraisals were excluded. Data regarding EOL criteria in these submissions were then gathered. The HTA decisions were divided into the following categories: EOL criteria met; EOL criteria not met; and EOL criteria not applicable. A chi-square analysis was performed. Results A total of 316 reviews were assessed in the final sample, of which 71 percent (n = 223) of decisions were positive. Out of the positive decisions, 43 percent (n = 96), 25 percent (n = 55), and 32 percent (n = 72) of decisions were in the EOL criteria met, EOL criteria not met, and EOL criteria not applicable groups, respectively. The chi-square analysis showed a significant correlation between HTA decisions and EOL criteria (p = 0.0008). These results were consistent when the “EOL criteria not applicable” group was excluded (p = 0.001). When the analysis was performed between the “EOL criteria met” and “EOL criteria not met”, along with “EOL criteria not applicable” groups, it showed a possible correlation (p = 0.05). Conclusions This study showed that in oncology, NICE reimburses treatments that meet EOL criteria more often than treatments that attempt, but fail, to meet the EOL criteria." @default.
• W4200325111 created "2021-12-31" @default.
• W4200325111 creator A5005546795 @default.
• W4200325111 creator A5037975807 @default.
• W4200325111 creator A5048581890 @default.
• W4200325111 date "2021-12-01" @default.
• W4200325111 modified "2023-10-18" @default.
• W4200325111 title "PP451 Does NICE Reimburse Oncology Treatments Meeting End-Of-Life Criteria More Often Than Treatments That Do Not?" @default.
• W4200325111 doi "https://doi.org/10.1017/s0266462321001604" @default.
• W4200325111 hasPublicationYear "2021" @default.
• W4200325111 type Work @default.
• W4200325111 citedByCount "0" @default.
• W4200325111 crossrefType "journal-article" @default.
• W4200325111 hasAuthorship W4200325111A5005546795 @default.
• W4200325111 hasAuthorship W4200325111A5037975807 @default.
• W4200325111 hasAuthorship W4200325111A5048581890 @default.
• W4200325111 hasBestOaLocation W42003251111 @default.
• W4200325111 hasConcept C112930515 @default.
• W4200325111 hasConcept C159110408 @default.
• W4200325111 hasConcept C17744445 @default.
• W4200325111 hasConcept C199360897 @default.
• W4200325111 hasConcept C199539241 @default.
• W4200325111 hasConcept C2777352838 @default.
• W4200325111 hasConcept C2779256446 @default.
• W4200325111 hasConcept C2779951463 @default.
• W4200325111 hasConcept C3019080777 @default.
• W4200325111 hasConcept C41008148 @default.
• W4200325111 hasConcept C512399662 @default.
• W4200325111 hasConcept C64332521 @default.
• W4200325111 hasConcept C71924100 @default.
• W4200325111 hasConceptScore W4200325111C112930515 @default.
• W4200325111 hasConceptScore W4200325111C159110408 @default.
• W4200325111 hasConceptScore W4200325111C17744445 @default.
• W4200325111 hasConceptScore W4200325111C199360897 @default.
• W4200325111 hasConceptScore W4200325111C199539241 @default.
• W4200325111 hasConceptScore W4200325111C2777352838 @default.
• W4200325111 hasConceptScore W4200325111C2779256446 @default.
• W4200325111 hasConceptScore W4200325111C2779951463 @default.
• W4200325111 hasConceptScore W4200325111C3019080777 @default.
• W4200325111 hasConceptScore W4200325111C41008148 @default.
• W4200325111 hasConceptScore W4200325111C512399662 @default.
• W4200325111 hasConceptScore W4200325111C64332521 @default.
• W4200325111 hasConceptScore W4200325111C71924100 @default.
• W4200325111 hasIssue "S1" @default.
• W4200325111 hasLocation W42003251111 @default.
• W4200325111 hasOpenAccess W4200325111 @default.
• W4200325111 hasPrimaryLocation W42003251111 @default.
• W4200325111 hasRelatedWork W1935811877 @default.
• W4200325111 hasRelatedWork W1984735078 @default.
• W4200325111 hasRelatedWork W2013151644 @default.
• W4200325111 hasRelatedWork W2073681061 @default.
• W4200325111 hasRelatedWork W2129750793 @default.
• W4200325111 hasRelatedWork W2133191722 @default.
• W4200325111 hasRelatedWork W2168886263 @default.
• W4200325111 hasRelatedWork W2331082360 @default.
• W4200325111 hasRelatedWork W2942977096 @default.
• W4200325111 hasRelatedWork W4311339034 @default.
• W4200325111 hasVolume "37" @default.
• W4200325111 isParatext "false" @default.
• W4200325111 isRetracted "false" @default.
• W4200325111 workType "article" @default.